Emergent BioSolutions (EBS) announced a contract modification has been secured to deliver CNJ-016 to the Administration for Strategic Preparedness and Response, part of the U. S. Department of Health and Human Services, for smallpox preparedness. ASPR exercised an option from its existing 10-year contract for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions expands NARCANDirect online distribution network
- Emergent BioSolutions Secures $62.4M ASPR Contract Modification
- Emergent BioSolutions secures $62.4M contract modification for BAT
- Emergent BioSolutions announces addition to Russell 3000 Index
- Emergent BioSolutions teams up with Victoria’s Voice Foundation